https://www.selleckchem.com/pr....oducts/sivelestat-so
Systemic inflammation and organ dysfunction/failure can complicate acute decompensation (AD) of cirrhosis with progression to acute-on-chronic liver failure (ACLF), leading to increased mortality. There are few studies on serum biomarkers predicting renal dysfunction (RD) or ACLF in AD. Serum cystatin C (CysC) and interleukin-6 (IL-6) were evaluated for predicting RD, ACLF, and mortality in AD patients. Consecutive AD patients seen from January 2018 to June 2019 were included. IL-6 and CysC were measured in serum at the time o
Like
Comment
Share
